This episode is a masterclass in applying scientific rigor to the longevity hype cycle. Darshan Shah, MD—a surgeon and longevity clinic founder—sits down with Matt Kaeberlein, a former University of Washington aging researcher who ran the Dog Aging Project and worked directly with the Interventions Testing Program (ITP), the field's most respected arbiter of what actually extends lifespan.
Kaeberlein walks through the evidence hierarchy for longevity interventions, starting with rapamycin, which he calls the most robustly validated molecule in aging biology. He explains why the ITP's genetically heterogeneous mouse model matters—it avoids the single-genotype confound that plagues most preclinical aging research—and why metformin's failure in that same program should temper enthusiasm. The conversation then moves to the risk-reward calculus that every biohacker and longevity-focused founder needs to internalize: how to weigh a molecule's known side-effect profile against the certain, compounding damage of biological aging.
The most actionable segment covers the peptide gray market. Kaeberlein draws a sharp line between oral small molecules with established safety data and injectable peptides sold for 'research use only.' He explains that without quality control, pharmacokinetic data, or human toxicology, compounds like BPC-157 and MOTS-c represent a fundamentally different risk category—one that most consumers don't understand. Shah pushes back from the clinician's perspective, creating a nuanced discussion about how physicians should navigate patients who are already using these compounds.
Listeners will leave with a decision-making framework for evaluating any longevity intervention: demand ITP-grade evidence, understand the difference between healthspan and lifespan data, and never confuse a mechanism with an outcome.
Key Insights
- The Interventions Testing Program (ITP) remains the gold standard for aging biology: rapamycin is the most robust and reproducible molecule for lifespan extension in mice, while metformin failed to extend lifespan in the ITP's genetically heterogeneous models.
- Kaeberlein frames the longevity risk calculus as asymmetric: for a 50-year-old, the known risks of rapamycin (mild oral ulcers, lipid changes) are far lower than the certain damage of biological aging, yet most physicians won't prescribe it because they're trained to treat disease, not optimize healthspan.
- The 'research use only' peptide market is a regulatory gray zone creating real danger—compounds like BPC-157 and MOTS-c lack human safety data, quality control is nonexistent, and Kaeberlein warns that injecting uncharacterized peptides is fundamentally different from taking an oral small molecule with decades of safety data.
- NAD+ precursors (NMN, NR) show strong effects in animal models of metabolic dysfunction but minimal impact in healthy organisms—Kaeberlein argues the human data doesn't support the current hype and that most people taking these supplements are likely wasting money.
- The Dog Aging Project's real-world evidence model is a new paradigm: by studying rapamycin in companion dogs living in normal environments, researchers can capture aging outcomes that better translate to humans than lab mouse studies, while simultaneously generating owner-reported healthspan data at scale.
- Epigenetic clocks are not yet actionable biomarkers—Kaeberlein explains they can be influenced by transient factors like exercise or fasting, making them unreliable for individual decision-making about whether an intervention is working.
Who should listen: Founders, investors, and clinicians who need a rigorous framework for separating longevity science from dangerous hype—and who may already be fielding questions about rapamycin, NAD+, or gray-market peptides.
Why This Matters
Kaeberlein's framework maps directly to how disciplined founders evaluate any emerging technology: separate mechanism from outcome, demand reproducible evidence, and never confuse a strong signal in a broken model for proof that something works in the real world. The peptide gray market is a case study in what happens when regulatory lag meets desperate demand—a pattern we see across frontier tech.
